General Medicine debuts as a platform where consumers can shop for medical care: While the healthcare marketplace concept isn’t new, the startup could have an upper hand by allowing people to see prices for medical care based on their unique health insurance details.
Cleveland Clinic forces upfront copays for service beginning in June: The strict payment policy means routine appointments will be cancelled or rescheduled for those who cannot afford to pay up front. It also risks forcing patients to delay care or go to the ER.
Ambience Healthcare’s AI model beats docs at medical coding accuracy: More accurate medical coding reduces billing errors, claims denials and delayed payments for health systems. We think it’s the next healthcare AI advancement that’s already demonstrating clear value..
Retail pharmacy reputations continue to slide: Even though retail pharmacies are rated poorly by consumers, pharmacists are still trusted sources. Newer pharmacy models create opportunities for drugmakers to build closer ties with pharmacists.
Novo, Lilly, and PBMs take steps to reduce GLP-1 drug prices: Players in the weight loss drug market are likely OK with cutting back on prices considering the potential to reach tens of millions of patients.
Clinicians want more support from pharma, but not via in-person sales meetings: Marketers need to create content that will proactively answer doctors’ questions about a drug’s cost/insurance coverage and how patients are responding to the treatment.
Medtronic spins out diabetes business into D2C company: Amid growing diabetes diagnoses, Medtronic is doubling down on its focus with a device company dedicated to helping consumers with diabetes.
Pharma companies are facing drug pricing and tax revenue pressure from Trump and Congress: As Trump rolls out new drug pricing executive orders, companion bills in Congress are amplifying pressure on the industry, driving companies closer to decide whether to negotiate or push back in court.
Gen Z, millennials are least likely to take health concerns to their PCP: Healthcare marketers need to show them where to get low-cost care while warning against overtrusting online medical information.
FDA’s approval process for new COVID-19 vaccines will soon get tougher: But the impact to leading vaccine makers like Pfizer and Moderna might be minimal. Here’s why.
Drug developers relocate clinical trials amid Trump’s NIH research and funding cuts: The final damage to research pipelines is still to be determined, but biotech and pharma companies are already reacting, and more may consider doing so given the uncertainty.
Out-of-home ads help pharma reach patients beyond clinical settings: Marketers must keep in mind that it’s not about pressure to convert—it's about creating presence and trust.
Novo Nordisk’s CEO steps down: Investor panic and a slumping stock may have been driving factors. Despite falling behind Eli Lilly in the weight loss drug market, recent moves around oral GLP-1 development put Novo in a strong position.
Omada Health is the latest prominent digital health player to go public in 2025: While healthcare companies are weathering the uncertain economic environment, Omada and Hinge must prove their programs for chronic condition management can be worthwhile long-term investments.
At-home injectable drugs have been getting more approvals: Amneal Pharmaceuticals is the latest to gain approval for its migraine treatment. Pharma companies can help spur uptake for at-home injectables like it with more education and support.
UnitedHealth Group faces reported criminal investigation over Medicare billing fraud: The DOJ may have gathered enough evidence against UnitedHealth, such as allegedly giving doctors kickbacks. Other top players in the Medicare Advantage market should be worried.
Pharma waits idly following Trump’s drug pricing executive order: Trump hopes pharma will lower US drug prices to align with what other countries pay. But the impact of the order could come down to how much authority the administration has without congressional approval.
The FDA pushes aggressive timeline to implement AI-assisted drug reviews: The FDA plans to speed up drug reviews with AI by the end of June, but pharma companies already concerned about the impact of layoffs and recent drug approval delays shouldn’t see it as a silver bullet.
UnitedHealth Group CEO Andrew Witty steps down: New leadership will aim to straighten out the company’s Medicare Advantage business to appease Wall Street. But we’re also keeping an eye on what they’ll do to improve UHG’s sinking reputation.
Consumers have unfavorable views of drugmakers and health insurers: But these companies are simultaneously getting higher brand equity. Their growth is predicated on revenue-driving actions that consumers believe lead to high healthcare prices.